1. SEIKAGAKU CORPORATION
  2. Investors
サブ-ナビゲーション
  • TOP
  • News Release
  • Who we are
  • ”Hyaluronic Acid” Expedition
  • What is Glycoscience
  • Our R&D
  • Management Policy
  • Highlights
  • Stock Information
  • ->Investors
    • News Release
    • What's New
    • Management Policy
    • Highlights
    • IR Library
    • IR Schedule
    • Shareholder Information
    • IR E-mail Alert
  • Our Company
  • Privacy Policy
  • Terms of Use
  • Sitemap

Investors

Financial Results

FY2020

  • Consolidated Financial Results (Summary) for the Third Quarter of Fiscal Year Ending March 31, 2021 (Nine-Month Period Ended December 31, 2021) (133KB)
  • Presentation Material for the Briefing on the Third Quater FY2020 Financial Results (2,456KB)

Next Schedule

May 13, 2021   Announcement of FY2020 Financial Results(Plan)

  • Disclaimer

Reuters (Minimum 15 minute delay)

News Release

      
  • 03.23.2021 Ono and Seikagaku Announce a Manufacturing and Marketing Approval in Japan for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint) pdf (114KB)

    読む Ono and Seikagaku Announce a Manufacturing and Marketing Approval in Japan for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint)

  • 02.05.2021 Consolidated Financial Results for the Thrid Quarter of Fiscal year 2020 pdf (133KB)

    読む Consolidated Financial Results for the Thrid Quarter of Fiscal year 2020

  • 02.05.2021 Seikagaku Announces Forecast of Consolidated Financial Results and Dividend Forecast pdf (86KB)

    読む Seikagaku Announces Forecast of Consolidated Financial Results and Dividend Forecast

  • 11.11.2020 Consolidated Financial Results for the Second Quarter of Fiscal Year 2020

    読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2020

More

What's New

      
  • 04.01.2021 Seikagaku will announce the financial results for the Fiscal Year ended March 31, 2021 at 16:00 on May 13, 2021.

    読む Seikagaku will announce the financial results for the Fiscal Year ended March 31, 2021 at 16:00 on May 13, 2021.

  • 02.05.2021 Seikagaku announced the financial results for the Third Quarter of the Fiscal Year ending March 31, 2021

    読む Seikagaku announced the financial results for the Third Quarter of the Fiscal Year ending March 31, 2021

  • 01.06.2021 Seikagaku will announce the financial results for the Third Quarter of the Fiscal Year ending March 31, 2021 at 15:00 on February 5, 2021.

    読む Seikagaku will announce the financial results for the Third Quarter of the Fiscal Year ending March 31, 2021 at 15:00 on February 5, 2021.

  • 12.02.2020 New Message from President & CEO

    読む New Message from President & CEO

More

Message from President & CEO

Message from President & CEO

Corporate Report

Corporate Report

Mid-term Management Plan

Mid-term Management Plan

Who we are

Who we are

R&D Pipeline

R&D Pipeline
Management Policy

Message from President & CEO

Mid-term Management Plan

R&D Pipeline

Profit Distribution Policies

Business Risks

Highlights

Business Performance

Business Performance(Quarter)

Cash Flow

Business Performance Data Download

IR Library

Summary of Financial Results

Presentation Material

Corporate Report

Shareholder Information

Stock Information

Shareholder Composition

Profit Distribution

General Meeting of Shareholders

Analyst Coverage

Stock Price

IR Schedule

Disclosure Policy

About RSS Feeds

IR E-mail Alert

More

Stock Price

More

This link will direct you to a third-party site.(Another window opens.)

Please click here

Step back to the Seikagaku Corporation website

The Seikagaku Corporation website uses cookies to personalize contents and offer a better browsing experience. Please click the Accept botton. (Read more)

Accept

生化学工業株式会社
  • 日本語
  • ”Hyaluronic Acid” Expedition
  • Contact Us 

Who we are

What is Glycoscience

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

Glycoscience in one minute

Glycoscience in one minute

”Hyaluronic Acid” Expedition

”Hyaluronic Acid” Expedition

Our R&D

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

R&D Basic Policy

R&D Basic Policy

R&D Pipeline

R&D Pipeline

Investors

Investors

News Release

What's New

Management Policy

Highlights

IR Library

IR Schedule

Shareholder Information

IR E-mail Alert

Message from President & CEO

Message from President & CEO

Our Company

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

Corporate Philosophy

Corporate Philosophy

Business Activities

Business Activities
生化学工業株式会社

Who we are

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

  • Part 1 Invitation to Glycoscience
  • Part 2 Fertilization
  • Part 3 Source of Energy
  • Part 4 Extracellular matrix 1
  • Part 5 Extracellular matrix 2
  • Part 6 Cell proliferation and differentiation
  • Part 7 Blood type
  • Part 8 Cancer
  • Part 9 Viral infection
  • Part 10 Applications and Developments

”Hyaluronic Acid” Expedition

Hyaluronic Acid - I am also in your home

Hyaluronic Acid- Everywhere in your body

Hyaluronic Acid- This is what I am!

Hyaluronic Acid- How I work in your body

Story Time

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

Investors

News Release

What's New

Management Policy

  • Message from President & CEO
  • Mid-term Management Plan
  • R&D Pipeline
  • Profit Distribution Policies
  • Business Risks

Highlights

  • Business Performance
  • Business Performance(Quarter)
  • Cash Flow
  • Business Performance Data Download

IR Library

  • Summary of Financial Results
  • Presentation Material
  • Corporate Report

IR Schedule

Shareholder Information

  • Stock Information
  • Shareholder Composition
  • Profit Distribution
  • General Meeting of Shareholders
  • Analyst Coverage
  • Stock Price

IR E-mail Alert

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

  • Business Segment
  • Products
    • Pharmaceuticals and Medical Devices
    • Bulk Products
      • Sodium Hyaluronate
      • Sodium Chondroitin Sulfate
    • Endotoxin-detecting reagents
  • Production
  • Quality Compliance
  • Contact Us
  • 日本語
To page top
To page top

Who we are

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

”Hyaluronic Acid” Expedition

Hyaluronic Acid - I am also in your home

Hyaluronic Acid- Everywhere in your body

Hyaluronic Acid- This is what I am!

Hyaluronic Acid- How I work in your body

Story Time

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

Investors

News Release

What's New

Management Policy

Highlights

IR Library

IR Schedule

Shareholder Information

IR E-mail Alert

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

Copyright © SEIKAGAKU CORPORATION All rights Reserved.

  • Privacy Policy
  • Terms of Use